Intellia Therapeutics (NTLA) Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Current Assets data on file, last reported at $466.4 million in Q1 2026.

• On a quarterly basis, Current Assets fell 15.41% year-over-year to $466.4 million in Q1 2026; TTM through Mar 2026 was $466.4 million, a 15.41% decrease from a year earlier, with the FY2025 full-year figure at $527.7 million, down 17.53% from the prior year.
• Current Assets for Q1 2026 stood at $466.4 million, down from $527.7 million in the prior quarter.
• Over the last five years, Current Assets for NTLA reached as high as $1.2 billion in Q4 2022 and fell as low as $466.4 million in Q1 2026.
• Historically, Current Assets has averaged $779.8 million across 5 years, with a median of $858.9 million in 2022.
• Across the five-year window, Current Assets surged 62.98% in 2022 and plunged 37.63% in 2025, its largest moves.
• Year by year, Current Assets stood at $1.2 billion in 2022, then fell by 17.95% to $998.3 million in 2023, then plunged by 35.91% to $639.9 million in 2024, then retreated by 17.53% to $527.7 million in 2025, then slipped by 11.61% to $466.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $466.4 million in Q1 2026, $527.7 million in Q4 2025, and $581.9 million in Q3 2025.